Valion Bio (VBIO) Price to Sales (2021 - 2026)

Valion Bio has reported Price to Sales for 6 years, with the latest figure at 1.8 in Q2 2026.

• On a quarterly basis, Price to Sales fell 3.31% year-over-year to 1.8 in Q2 2026; TTM through Jun 2026 was 0.2, a 42.29% decrease from a year earlier, with the FY2025 full-year figure at 0.18, up 102.29% from the prior year.
• Price to Sales was 1.8 for Q2 2026 at Valion Bio, up from 0.84 in the prior quarter.
• The five-year high for Price to Sales was 2484.95 in Q1 2022, with the low at 0.38 in Q4 2024.
• Average Price to Sales over 5 years is 293.22, with a median of 4.96 recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Price to Sales sank 99.78% in 2023, then soared 122.91% in 2025.
• Over 5 years, Price to Sales stood at 10.32 in 2022, then plunged by 73.66% to 2.72 in 2023, then plunged by 86.18% to 0.38 in 2024, then jumped by 122.91% to 0.84 in 2025, then jumped by 115.18% to 1.8 in 2026.
• The last three Price to Sales figures came in at 1.8 (Q2 2026), 0.84 (Q4 2025), and 1.05 (Q3 2025), per Business Quant data.